BI 905711 / Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 905711 / Boehringer Ingelheim
NCT05087992: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Completed
1
13
Europe, Japan, US, RoW
BI 905711, FOLFIRI, Bevacizumab
Boehringer Ingelheim
Gastrointestinal Cancer, Metastatic
10/23
11/23
NCT04137289: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

Completed
1
110
Europe, Japan, US, RoW
BI 905711
Boehringer Ingelheim
Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
07/23
11/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 905711 / Boehringer Ingelheim
NCT05087992: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Completed
1
13
Europe, Japan, US, RoW
BI 905711, FOLFIRI, Bevacizumab
Boehringer Ingelheim
Gastrointestinal Cancer, Metastatic
10/23
11/23
NCT04137289: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

Completed
1
110
Europe, Japan, US, RoW
BI 905711
Boehringer Ingelheim
Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
07/23
11/23

Download Options